Spanish Registry of Mohs Surgery (REGESMOHS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02310503|
Recruitment Status : Completed
First Posted : December 8, 2014
Last Update Posted : May 5, 2020
REGESMOHS (Registro Español de cirugía de Mohs) aims at describing effectiveness of Mohs surgery, and patient, tumor and technique factors related to adverse events and tumor recurrence.
REGESMOHS is a prospective cohort, including all patients considered for Mohs surgery in participating centers. All consecutive patients are included. The only exclusion criteria are being under 18-years-old or legally incompetent. Pre-planned follow-up is as required by common clinical practice, but at least once a year for the study period.
|Condition or disease||Intervention/treatment|
|Skin Neoplasms Carcinoma, Basal Cell Carcinoma, Squamous Cell Dermatofibrosarcoma Melanoma Histiocytoma, Malignant Fibrous Neoplasms, Adnexal and Skin Appendage||Procedure: Mohs surgery|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||6000 participants|
|Target Follow-Up Duration:||4 Years|
|Official Title:||Spanish Registry of Mohs Surgery [Registro Español de Cirugía de Mohs]|
|Study Start Date :||July 1, 2013|
|Actual Primary Completion Date :||February 29, 2020|
|Actual Study Completion Date :||February 29, 2020|
Patients treated using Mohs surgery. Other exposures considered include patient characteristics, preoperative care and technical variants.
Procedure: Mohs surgery
A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
- Tumor recurrence [ Time Frame: 6 years ]
- Short term outcomes [ Time Frame: 1 month ]Bleeding, infection, abnormal scar, necrosis
- Use of resources [ Time Frame: During surgery ]Need for admission, type of anesthesia, number of surgical steps, participating doctors,time in surgery room.
- Impairments of body function and structure [ Time Frame: 6 years ]presence of: abnormal scar, ectropion, nostril alteration, oral sphincter incompetence,other
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02310503
|Hospital Universitario de Cruces|
|Hospital del Mar|
|Hospital Quirón Teknon|
|Hospital Santa Creu i Sant Pau|
|Complejo Hospitalario Universitario de Guadalajara|
|Complejo Asistencial Universitario de León|
|Hospital de la Princesa|
|Hospital Gregorio Marañon|
|Hospital La Zarzuela|
|Hospital Universitario Fundación de Alcorcón|
|Clínica Universitaria de Navarra|
|Complexo Hospitalario Universitario de Santiago|
|Santiago de Compostela, Spain|
|Instituto Valenciano de Oncología|
|Study Director:||Ignacio Garcia-Doval, MD, PhD||Research Unit. Academia Española de Dermatologia y Venereologia (Spanish Academy of Dermatology)|